PlainHospital

BECTON, DICKINSON & CO. (SPARKS)

Manufacturer adverse-event records for BECTON, DICKINSON & CO. come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.

FDA MAUDE device safety record · 2020–2026 · mid-book · quiet Death-code · injury-light

Injury-mix signature

BECTON, DICKINSON & CO. is lighter on Injury codes

Injury-coded event_type share is 0.8% (injury-light tercile) beside 0.01% Death-coded (quiet). Volume band: mid.

What the Injury-mix reading shows for BECTON, DICKINSON & CO. (SPARKS)

The standout signal for BECTON, DICKINSON & CO. (SPARKS) is Injury-mix: 0.8% Injury-coded (injury-light) beside 0.01% Death-coded, on a mid-book footprint.

Mid-pack volume still shows a clear device fingerprint; the table below is the actionable layer for BECTON, DICKINSON & CO.. Event_type Death/Injury codes differ from patient-outcome rows - see methodology.

Reports span 20 device types, led in this extract by Malfunction at 7,037 (99.1% of event_type total). Peak single-year volume reaches 2,065 reports across 7 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.

7,098
Total Reports
1
Event-type Death
60
Injury Reports
20
Device Types

Event Types

Malfunction 7,037 (99.1%)
Injury 60 (0.8%)
Death 1 (0.0%)

Patient Outcomes

FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.

6,611 (93.4%)
Other 426 (6.0%)
Required Intervention 37 (0.5%)
Death 1 (0.0%)

Devices (20)

Device Reports
Coronavirus Antigen Detection Test System. 1,526
System, Blood Culturing 1,117
Real Time Nucleic Acid Amplification System 959
System, Test, Automated, Antimicrobial Susceptibility, Short Incubation 778
Culture Media, Non-Selective And Non-Differential 506
Reagents, 2019-Novel Coronavirus Nucleic Acid 313
Equipment, Laboratory, General Purpose, Labeled Or Promoted For A Specific Medical Use 261
Susceptibility Test Powders, Antimycobacterial 207
Culture Media, Selective And Differential 154
Calculator/Data Processing Module, For Clinical Use 140
Kit, Dna Detection, Human Papillomavirus 108
Culture Media, Enriched 95
Culture Media, Antimicrobial Susceptibility Test, Excluding Mueller Hinton Agar 90
Culture Media, Selective And Non-Differential 83
Covid-19 Multi-Analyte Antigen Device 72
Processor, Cervical Cytology Slide, Automated 62
Antigens, All Groups, Streptococcus Spp. 52
Culture Media, Non-Selective And Differential 52
Nephelometer, For Clinical Use 45
Gram Negative Identification Panel 41

Yearly Trend

20
2020: 897
21
2021: 2,065
22
2022: 1,678
23
2023: 1,011
24
2024: 322
25
2025: 1,056
26
2026: 69

Read our methodology - how this data is sourced, computed, and verified.